The newly identified ceRNA axis (AC005332.1 and AC012615.1/hsa-miR-100-5p/ORAOV1) offers novel therapeutic opportunities, such as miRNA mimics or lncRNA inhibitors, to suppress ORAOV1 and inhibit HCC progression. The gene discussed is LTO1; the disease is hepatocellular carcinoma.